Luigi G. Cecchi

Via Manzoni 56, Rozzano
Milan, 20089, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.

Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.

Journal: European journal of nuclear medicine and molecular imaging
Published: March 20, 2026

Correction: Cecchi et al. Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions. Cancers 2025, 17, 3199.

Correction: Cecchi et al. Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions. Cancers 2025, 17, 3199.

Journal: Cancers
Published: December 05, 2025

Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions.

Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions.

Journal: Cancers
Published: September 09, 2025

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.

Journal: bioRxiv : the preprint server for biology
Published: August 08, 2025

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.

Journal: The Journal of clinical investigation
Published: February 12, 2025

Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer.

Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer.

Journal: Oral oncology
Published: January 03, 2025

Somatic and germline genomic variation in thymic carcinomas.

Somatic and germline genomic variation in thymic carcinomas.

Journal: ESMO open
Published: November 06, 2024

Advancing Prostate Cancer Care: Prostate-specific Membrane Antigen-based Radioligand Therapy at the Forefront.

Advancing Prostate Cancer Care: Prostate-specific Membrane Antigen-based Radioligand Therapy at the Forefront.

Journal: European urology
Published: September 30, 2024

New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy.

New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
Published: June 11, 2024

Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy.

Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy.

Journal: Cancers
Published: October 03, 2023

Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs.

Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs.

Journal: Frontiers in immunology
Published: September 03, 2023
Showing 1-11 of 11

Last Updated: 09/26/2026